Vancouver, British Columbia – (December 7th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that it has retained Questrade, Inc. (“Questrade”) to provide market-making services in accordance with CSE guidelines.
The term of the agreement is for one year, beginning December 7, 2020 at a cost of CAD $3,000 per month. Either party may terminate the agreement with 30 days written notice. Though BioMark and Questrade are unrelated and unaffiliated entities and Questrade will not receive shares or options as compensation from the Company, Questrade and its clients have or may have a direct interest in the securities of BioMark.
About Questrade, Inc.
Questrade, Inc., provides Canadians with high-speed, direct access trading in the U.S. and Canadian stock and options markets through its IQ trading platforms. Questrade offers market making services on behalf of TSX, TSX Venture Exchange, and Canadian Securities Exchange listed companies, providing liquidity on the stock exchanges for shareholders.
Press Release -BIOMARK RETAINS QUESTRADE, INC. TO PROVIDE MARKET MAKING SERVICES